Figure 4.

Kaplan–Meier plots for biochemical relapse of a test set of patients stratified by prognostic models based on (a), clinical data alone, or (b), clinical data + 29-ERV panel obtained from a training set. Tumor-enriched samples from PCa patients from the Moffitt Cancer Center and the University of Toronto Sunnybrook Medical Centre (test set of n = 35, originating from different hospitals than those used for the training set) were separated into two risk groups for biochemical relapse. The prognostic model applied to the test set in (b) (p = 7.362 × 10⁻¹¹) significantly outperforms clinical parameters alone, in (a) (p = 0.05323).